I think you read updates to the brief today - but I will re-iterate to see notes from today if you have not under "additional information" and dated 11/5.
I would say that the general feedback given to overall design from a team meeting was on less focus on hexagon, more focus on the U and the I or even tying them together somehow, making them stand out as a combo....We decided to use GENUINE or another name RUBICON for our first trial of ublituximab and Ibrutinib....and UNITY for a different trial (combines Ublituximab and TGR-1202 for U and T).
That said however - for GENUINE - remember the importance of the U and the I being key. We like the word and what it stands for - we see the chance to highlight "our" drug with "U" (an antibody) and the idea of a combo with the I drug (a BCR receptor inhibitor of BTK - less important). Maybe even tying them together somehow. Please see the updated comments at brief about that and also about focusing on the science behind the drugs possibly (shapes of the pathways inhibited - search antiCD20 antibody or BCR receptor) in the logo or any design element. It is valuable feedback from our CEO, COO and team to make a decision with me. THANKS AGAIN!
Thanks again. I am getting ready to be back 100% tomorrow...will be getting these top designs to our team but they will not see until Monday. More to come.